A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)

Inclusion Criteria: * Histologically or cytologically documented metastatic NSCLC AC (as defined by the 8th International Association for the Study of Lung Cancer Classification). * Measurable target disease assessed by the investigator according to RECIST 1.1. * Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 Exclusion Criteria: * NSCLC histologies other than AC (ie, squamous cell carcinoma, large cell carcinoma). * Significant third-space fluid retention (eg, ascites or pleural effusion) that requires repeated drainage. * Prior pneumonectomy. Prior lobectomy and segmentectomy are allowed \> 12 months before treatment. * Recent chest radiotherapy. Participants with chest or chest wall radiation may be permitted if chest radiation is documented \> 6 months before starting study treatment. Other protocol-defined inclusion/exclusion criteria apply.